Plasma thrombin-antithrombin complex as a candidate biomarker for coronary slow flow

血浆凝血酶-抗凝血酶复合物作为冠状动脉慢血流的候选生物标志物

阅读:1

Abstract

BACKGROUND: Coronary slow flow (CSF), characterized by delayed coronary perfusion without significant coronary artery stenosis, remains a diagnostic challenge due to its elusive pathophysiology. This retrospective study aimed to evaluate the association between the thrombin-antithrombin (TAT) complex and CSF. PATIENTS AND METHODS: Ninety-one CSF patients and 74 subjects with normal coronary flow were recruited in this cohort. Coronary artery blood flow was quantified using the thrombolysis in myocardial infarction frame count (TFC) method. Plasma TAT complex levels were measured via chemiluminescent immunoassay. Logistic regression analyses and a receiver operating characteristic (ROC) curve were performed to determine the predictive value of TAT for CSF. RESULTS: Compared with patients without CSF, patients with CSF showed higher plasma levels of TAT complex, total cholesterol, and low-density lipoprotein cholesterol, all of which were also positively correlated with TFC. However, multivariate logistic regression identified TAT as the only independent predictor of CSF after adjustment (OR: 1.71, 95% CI: 1.39-2.10, p < 0.001). More specifically, ROC analysis revealed that a plasma TAT complex levels of 3.875 ng/ml predicted CSF with a specificity of 89.2% and a sensitivity of 62.6%. CONCLUSION: Elevated plasma TAT complex levels are strongly associated with CSF and may serve as a candidate diagnostic biomarker.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。